Antimicrobial Susceptibilities of a Worldwide Collection of <i>Stenotrophomonas maltophilia</i> Isolates Tested against Tigecycline and Agents Commonly Used for <i>S. maltophilia</i> Infections

Abstract

Antimicrobial susceptibilities were determined for 1,586 isolates of Stenotrophomonas maltophilia from globally diverse medical centers using the Clinical Laboratory Standards Institute broth microdilution method. The combination trimethoprim-sulfamethoxazole (96.0% of isolates susceptible at < or =2 microg/ml trimethoprim and 38 microg/ml sulfamethoxazole) and tigecycline (95.5% of isolates sussceptible at < or =2 microg/ml) were the only antimicrobials tested with >94% susceptibility in all regions. Susceptibility rates for other commonly used were lower than expected and varied geographically. This in vitro data supports tigecycline as a potential candidate for clinical investigations into S. maltophilia infections.